Profile data is unavailable for this security.
About the company
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
- Revenue in USD (TTM)0.00
- Net income in USD-75.52m
- Incorporated2018
- Employees51.00
- LocationAerovate Therapeutics Inc930 Winter Street, Suite M-500WALTHAM 02451United StatesUSA
- Phone+1 (617) 443-2400
- Fax+1 (302) 655-5049
- Websitehttps://www.aerovatetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Korro Bio Inc | 0.00 | -81.17m | 565.54m | 101.00 | -- | 2.88 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| SNDL Inc | 661.67m | -122.38m | 578.29m | 2.52k | -- | 0.6612 | -- | 0.874 | -0.4698 | -0.4825 | 2.55 | 3.36 | 0.5995 | 5.29 | 36.58 | 262,986.00 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 579.54m | 186.00 | -- | 2.33 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Cabaletta Bio Inc | 0.00 | -67.68m | 580.85m | 101.00 | -- | 2.51 | -- | -- | -1.65 | -1.65 | 0.00 | 4.94 | 0.00 | -- | -- | 0.00 | -36.52 | -33.76 | -39.22 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 581.51m | 74.00 | -- | 2.25 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Absci Corp | 5.72m | -110.57m | 586.90m | 155.00 | -- | 2.74 | -- | 102.64 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Lyell Immunopharma Inc | 130.00k | -234.63m | 594.00m | 224.00 | -- | 0.9035 | -- | 4,569.25 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Aerovate Therapeutics Inc | 0.00 | -75.52m | 598.89m | 51.00 | -- | 5.29 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
| Stoke Therapeutics Inc | 8.78m | -104.70m | 602.48m | 110.00 | -- | 3.33 | -- | 68.61 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Castle Biosciences Inc | 219.79m | -57.47m | 607.47m | 610.00 | -- | 1.54 | -- | 2.76 | -2.15 | -2.15 | 8.20 | 14.27 | 0.488 | 7.55 | 7.12 | 360,308.20 | -12.76 | -9.43 | -14.07 | -10.17 | 79.53 | 80.58 | -26.15 | -28.46 | 6.04 | -- | 0.0003 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Zymeworks Inc | 76.01m | -118.67m | 618.18m | 272.00 | -- | 1.33 | -- | 8.13 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| GH Research PLC | 0.00 | -35.59m | 621.74m | 49.00 | -- | 2.84 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -100.70m | 629.05m | 100.00 | -- | 2.28 | -- | -- | -1.97 | -1.97 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -40.34 | -33.92 | -43.47 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 632.08m | 234.00 | -- | 3.86 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Aerovate Therapeutics Inc's reporting currency: US Dollar USD
57.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 8.26m | 29.66% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 1.68m | 6.03% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 1.21m | 4.35% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 1.06m | 3.80% |
| Great Point Partners LLCas of 31 Dec 2023 | 1.04m | 3.72% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 675.64k | 2.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 604.51k | 2.17% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 537.22k | 1.93% |
| Point72 Asset Management LPas of 31 Dec 2023 | 441.47k | 1.58% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 403.69k | 1.45% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
